VIP

Most Common Uses

Treatment of Respiratory Conditions

VIP has shown promise in managing respiratory disorders, particularly those involving airway constriction and inflammation. Its ability to relax smooth muscles in the lungs makes it a candidate for treating conditions like asthma and chronic obstructive pulmonary disease (COPD). Researchers are exploring VIP-based therapies to reduce airway resistance and improve breathing in affected patients.

Management of Inflammatory and Autoimmune Diseases

The peptide’s anti-inflammatory properties have sparked interest in its use for conditions such as rheumatoid arthritis, inflammatory bowel disease, and sepsis. VIP modulates immune responses, helping to reduce excessive inflammation while promoting immune balance. This makes it a potential therapeutic agent for diseases driven by immune system overactivity.

Neuroprotection and Neurological Disorders

VIP exhibits protective effects on nerve cells, supporting its potential in treating neurodegenerative conditions like Alzheimer’s and Parkinson’s disease. By promoting neuronal survival and reducing oxidative stress, VIP may help slow disease progression or alleviate symptoms. Its role in regulating brain inflammation also makes it relevant for conditions like multiple sclerosis.

Gastrointestinal Health

In the digestive system, VIP regulates gut motility, secretion, and blood flow. It is being studied for its potential to treat disorders like irritable bowel syndrome (IBS) and other motility-related conditions. Its ability to relax gastrointestinal smooth muscles may help relieve symptoms such as abdominal pain and irregular bowel movements.

Cardiovascular Applications

VIP acts as a vasodilator, meaning it helps widen blood vessels to improve blood flow. This property is being investigated for its potential in managing hypertension and heart failure. By reducing vascular resistance, VIP may support better cardiovascular function, particularly in conditions where blood vessel constriction is a concern.

Cancer Research

Emerging studies suggest VIP may influence certain types of cancer, particularly those affecting the lungs, pancreas, and prostate. Its role in regulating cell growth and immune responses makes it a candidate for adjunctive cancer therapies. However, research is ongoing to better understand its mechanisms and potential applications in oncology.

Wound Healing and Tissue Repair

VIP’s ability to promote blood flow and modulate immune responses has led to investigations into its role in wound healing. By enhancing tissue repair processes and reducing inflammation at injury sites, VIP could be used in treatments for chronic wounds or tissue damage caused by surgery or trauma.

Potential in Psychiatric Disorders

Due to its calming effects on the nervous system, VIP is being explored for its potential in managing anxiety and stress-related disorders. Its ability to regulate neurotransmitter release and reduce neuroinflammation may contribute to therapies for mood disorders or post-traumatic stress disorder (PTSD).

Mechanism of Action

VIP interacts with two types of receptors, VPAC1 and VPAC2, found on cells in places like the lungs, brain, gut, and immune system. When VIP connects with these receptors, it triggers a process that boosts cyclic adenosine monophosphate, or cAMP, inside cells. This increase activates protein kinase A, which modifies proteins to change how cells work, like relaxing muscles or tweaking gene activity.

One of VIP’s key roles is relaxing smooth muscles in organs such as blood vessels, airways, and the digestive tract. It does this through the cAMP pathway, which lowers calcium levels in muscle cells. Less calcium means muscles don’t contract, leading to wider blood vessels, open airways, and calmer gut movements. This effect makes VIP a promising option for conditions like asthma or high blood pressure.

VIP also helps balance the immune system by working with cells like T-cells, macrophages, and dendritic cells. It reduces inflammatory molecules like TNF-α and IL-6 while boosting anti-inflammatory ones like IL-10. This shift helps calm overactive immune responses, which could make VIP useful for treating inflammatory or autoimmune diseases.

In the brain, VIP supports nerve cells by encouraging the release of growth factors like BDNF, which help neurons grow and repair. It also protects against excitotoxicity, where too much neurotransmitter harms neurons, by stabilizing calcium and reducing inflammation. These properties suggest VIP could play a role in treating neurodegenerative disorders.

VIP also regulates the release of hormones, mucus, and digestive enzymes. In the gut, it promotes water and electrolyte secretion to aid digestion and keep things balanced. In the pancreas, it helps release insulin to manage blood sugar, all through cAMP-driven pathways that enhance cell activity.

Additionally, VIP aids tissue repair by encouraging the growth of new blood vessels and improving blood flow to damaged areas. It boosts production of growth factors like VEGF, which supports tissue regeneration, making it valuable for wound healing and recovery from injuries.

Structure and Pharmacology

VIP is a 28-amino-acid peptide belonging to the secretin-glucagon family of peptides. Its primary sequence, highly conserved across mammals, is H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2. The peptide features a linear, alpha-helical conformation, which facilitates its binding to specific receptors. The N-terminal region, particularly the first few amino acids, is essential for receptor activation, while the C-terminal region stabilizes the peptide’s structure. This compact, stable structure allows VIP to interact effectively with its target receptors in various tissues.

VIP is rapidly degraded in the body, primarily by peptidases such as dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP), resulting in a short plasma half-life of approximately one to two minutes. This rapid clearance occurs in the liver, kidneys, and lungs, where enzymes break down the peptide into inactive fragments. VIP is typically administered through inhalation or intravenous routes in experimental settings to bypass gastrointestinal degradation and achieve therapeutic concentrations. Its short half-life poses challenges for clinical use, prompting research into stabilized analogs and delivery systems, such as liposomes or nanoparticle carriers, to prolong its activity.

The pharmacological effects of VIP stem from its ability to modulate multiple physiological processes. It promotes smooth muscle relaxation in the airways, blood vessels, and gastrointestinal tract, facilitating bronchodilation, vasodilation, and reduced gut motility. VIP also exerts anti-inflammatory effects by suppressing pro-inflammatory cytokine production and enhancing anti-inflammatory cytokine release in immune cells. In the nervous system, it supports neuronal survival and reduces neuroinflammation, contributing to neuroprotection. Additionally, VIP stimulates secretion of water, electrolytes, and hormones, such as insulin, in various tissues. These diverse effects make VIP a versatile candidate for therapeutic applications.

Dosages

VIP is primarily used in research and experimental clinical settings, with limited standardized dosing protocols due to its investigational status. The following outlines current approaches to VIP dosing based on available studies and therapeutic applications, focusing on its administration in specific contexts.

VIP is typically administered via intravenous infusion or inhalation to achieve effective concentrations, as its short half-life limits oral use. Intravenous delivery is common in systemic conditions like sepsis or pulmonary hypertension, while inhalation is preferred for respiratory disorders such as asthma. Subcutaneous or intramuscular routes are less common due to rapid degradation.

In human studies, VIP dosages vary depending on the condition and administration method. Most commonly, VIP is dosed 25–100 micrograms per administration, used for 2 to 4 weeks for potential treatment of short-term conditions, while longer-term use can be 3 to 6 months.

Warnings and Cautions

VIP can significantly lower blood pressure due to its vasodilatory effects, which may cause hypotension, dizziness, or fainting, especially in patients with existing cardiovascular issues. Blood pressure and heart rate need careful monitoring during administration, particularly with intravenous infusions. Those with hypotension or heart failure require close supervision to prevent worsening of their condition.

VIP’s short half-life makes maintaining consistent therapeutic levels challenging. Overdosing to counter this may lead to side effects like flushing, headaches, or gastrointestinal discomfort. Precise dosing, often through continuous infusions or specialized delivery systems, is important to ensure efficacy while minimizing risks.

Though rare, allergic reactions to VIP or its delivery methods, such as nebulized formulations, can occur. Symptoms like rash, itching, or respiratory distress warrant immediate discontinuation and medical evaluation. Patients with a history of peptide allergies or hypersensitivity to related compounds need careful monitoring.

VIP’s effects on smooth muscle relaxation and immune modulation may interact with medications affecting blood pressure, immune function, or gut motility. Combining VIP with other vasodilators or anti-inflammatory drugs could amplify effects, leading to unintended outcomes. A thorough review of a patient’s medications is essential before starting VIP therapy.

Limited data are available on VIP’s use in pregnant or breastfeeding women, children, or the elderly. Its effects on developing fetuses, infants, or aging physiology remain poorly studied, so caution is needed. VIP should only be used in these groups when benefits clearly outweigh risks, with close medical oversight.

Research & Clinical Trials

VIP Boosts Secretion and Eases Radiation Gut Damage

VIP is an important regulator of intestinal health, with major roles in both maintaining normal homeostasis and supporting recovery after injury. Under steady-state conditions, VIP was found to influence the balance of epithelial cell populations by promoting differentiation toward secretory cell types, particularly Paneth and goblet cells, through activation of the p38 MAPK pathway. At the same time, it regulated the number and proliferative activity of Lgr5+ intestinal progenitor cells, which are critical for ongoing tissue renewal and stability of the intestinal lining.

When the intestine was exposed to irradiation-induced injury, these progenitor cells became even more sensitive to the effects of VIP, allowing the peptide to strongly enhance epithelial regeneration. This regenerative capacity was not only observed in organoid cultures in vitro but was also confirmed in live mouse models, where treatment with VIP significantly reduced structural damage and preserved intestinal function following abdominal irradiation.

Taken together, these findings position VIP as a central mediator of neuroepithelial communication in the gut, directly linking signals from the enteric nervous system to epithelial stem and progenitor cell behavior. Beyond its well-known physiological effects on motility, secretion, and vascular tone, VIP emerges as a key factor in regulating progenitor cell dynamics and promoting repair after injury. This suggests that targeting VIP signaling could hold therapeutic potential for conditions involving epithelial damage, such as radiation-induced injury, inflammatory diseases, or other disorders that compromise intestinal integrity. [1]

VIP’s Role in Ulcerative Colitis via IL-10 in B Cells

VIP is a crucial regulator of intestinal health, playing a dual role in maintaining normal epithelial balance and supporting tissue regeneration after injury. Under normal physiological conditions, VIP promotes differentiation of epithelial cells toward secretory lineages, especially Paneth and goblet cells, primarily through the p38 MAPK signaling pathway. At the same time, it regulates the number and proliferative activity of Lgr5+ intestinal progenitor cells, which are essential for continuous tissue renewal and long-term maintenance of the gut lining.

When the intestine is exposed to stress or damage, such as irradiation-induced injury, these progenitor cells become increasingly responsive to VIP. This heightened sensitivity allows VIP to significantly enhance epithelial regeneration, accelerating the repair process. Evidence from both organoid culture systems and in vivo mouse models demonstrated that VIP treatment not only stimulated regeneration but also substantially reduced tissue injury and preserved intestinal function after radiation exposure.

Overall, the findings highlight VIP as a central mediator of communication between the enteric nervous system and the intestinal epithelium. By directly influencing progenitor cell behavior, VIP links neural activity to epithelial renewal and recovery. Beyond its established physiological functions in motility and secretion, VIP is now recognized as a key factor in epithelial repair mechanisms. This positions VIP as a promising therapeutic target for conditions characterized by epithelial damage, including radiation-induced intestinal injury, chronic inflammation, and other disorders that disrupt intestinal integrity. [2]

VIP Advances in GI Physiology and Pathophysiology

This study concluded that vasoactive intestinal peptide (VIP) is a widely distributed neuropeptide with critical roles in gastrointestinal (GI) physiology and pathology. Originally identified as a vasodilator, VIP is now recognized as a multifunctional regulator of epithelial, neuronal, endocrine, and immune cell function. Through its receptors, VPAC1 and VPAC2, VIP influences a broad range of GI processes, including epithelial secretion, intestinal motility, mucosal blood flow, immune regulation, and barrier function. Genetic studies in knockout mice revealed that the absence of VIP or its receptors disrupts circadian rhythm, epithelial proliferation, mucus production, intestinal motility, and immune balance, underscoring its essential role in both homeostasis and disease.

The review highlights that VIP signaling through VPAC1 primarily controls epithelial ion transport, mucus secretion, and immune cell regulation, while VPAC2 is more strongly linked to smooth muscle relaxation, vasodilation, and circadian regulation. Dysregulation of VIP signaling contributes to pathologies such as diarrhea (seen in VIP-secreting tumors), colitis, abnormal intestinal growth, and metabolic disturbances. Conversely, controlled activation of VIP pathways shows therapeutic promise for conditions including inflammatory bowel disease, autoimmune disorders, diabetes, and even cancer. [3]